Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Ranbaxy’s First Biosimilar Target Will Be Amgen’s Neupogen

Feb 08 2007

• By Shirley Haley

Related Content

Just A Product, Not A Pathway, FDA Says Of Omnitrope Approval

May 31 2006

Dr. Reddy’s Tops Billion Dollar Mark In First Nine Months Of Fiscal 2007

Jan 23 2007

Hospira, Stada Collaboration To Yield Biosimilar EPO In The EU Ahead Of U.S.

Nov 20 2006

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window